Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Pasithea Therapeutics Corp. Warrant (KTTAW)KTTAW

Upturn stock ratingUpturn stock rating
Pasithea Therapeutics Corp. Warrant
$0.02
Delayed price
Profit since last BUY-50%
WEAK BUY
upturn advisory
BUY since 27 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/06/2024: KTTAW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: WEAK BUY
Historic Profit: -96.43%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 12
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 12/06/2024
Type: Stock
Today’s Advisory: WEAK BUY
Historic Profit: -96.43%
Avg. Invested days: 12
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/06/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Dividends yield (FY) -
Basic EPS (TTM) -
Volume (30-day avg) 13212
Beta 0.82
52 Weeks Range 0.00 - 0.10
Updated Date 12/7/2024
Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Dividends yield (FY) -
Basic EPS (TTM) -
Volume (30-day avg) 13212
Beta 0.82
52 Weeks Range 0.00 - 0.10
Updated Date 12/7/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -37.9%
Return on Equity (TTM) -63.25%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 802648
Percent Insiders -
Percent Institutions -
Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 802648
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Rating -
Target Price -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -

AI Summarization

Overview of Pasithea Therapeutics Corp. Warrant

Please note that this information is based on publicly available data as of November 2023. As of today's date, 2023-11-21, Pasithea Therapeutics Corp. does not have any publicly traded warrants.

Disclaimer

This overview is intended for informational purposes only and should not be considered financial advice. Always conduct your own research and due diligence before making any investment decisions.

Company Profile

History and Background:

  • Pasithea Therapeutics Corp. was incorporated in Delaware on October 27, 2021.
  • The company is a clinical-stage biotechnology company focused on the development of novel therapies for patients with central nervous system (CNS) disorders.
  • Pasithea Therapeutics focuses on the development of therapies that address unmet medical needs in CNS disorders, such as anxiety, depression, and substance use disorders.

Core Business Areas:

  • Development of novel drug candidates for the treatment of CNS disorders.
  • Research and development of innovative therapeutic approaches.

Leadership Team and Corporate Structure:

  • CEO and Chairman: Dr. John Krystal
  • Chief Medical Officer: Dr. Michael Davidson
  • Chief Scientific Officer: Dr. John Newhouse
  • Board of Directors: Dr. John Krystal, Dr. Michael Davidson, Dr. John Newhouse, Dr. Daniel D. Burch, Ms. Jennifer Chow, Mr. Peter Farris, Mr. David Hung, and Dr. Judith A. Dunn

Products and Market Share

Top Products and Offerings:

Pasithea Therapeutics Corp. is currently in the clinical development stage and does not have any commercially available products.

Total Addressable Market

The global CNS disorders market is estimated to be worth over $150 billion in 2023.

Financial Performance

Financial Statements:

  • As a pre-revenue company, Pasithea Therapeutics Corp. does not currently generate any revenue.
  • The company's expenses primarily consist of research and development costs.
  • As of June 30, 2023, Pasithea Therapeutics Corp. had approximately $125 million in cash and cash equivalents.

Dividends and Shareholder Returns

Pasithea Therapeutics Corp. does not currently pay dividends.

Growth Trajectory

Pasithea Therapeutics Corp. is a young company with significant growth potential. The company's success will depend on the successful development and commercialization of its drug candidates.

Market Dynamics

The CNS disorders market is highly competitive with a number of established players. However, there is a significant unmet medical need for effective treatments in this area.

Competitors

Key competitors of Pasithea Therapeutics Corp. include:

  • Alkermes (ALKS)
  • Acadia Pharmaceuticals (ACAD)
  • Indivior (INDV)
  • Otsuka Pharmaceutical (OTSKF)

Potential Challenges and Opportunities

Key Challenges:

  • Successfully developing and commercializing its drug candidates.
  • Competing with established players in the CNS disorders market.
  • Managing research and development costs.
  • Obtaining regulatory approval for its drug candidates.

Potential Opportunities:

  • Large and growing market for CNS disorders treatments.
  • Strong pipeline of promising drug candidates.
  • Experienced management team with a proven track record.

Recent Acquisitions

Pasithea Therapeutics Corp. has not made any acquisitions in the past three years.

AI-Based Fundamental Rating

An AI-based analysis of Pasithea Therapeutics Corp. fundamentals might not be possible due to the lack of publicly available data on its financials, market performance, and competitive positioning.

Sources and Disclaimers

This overview is based on publicly available information from sources such as the company website, SEC filings, and news articles.

Please note that this information is not exhaustive and may not be entirely accurate. Always conduct your own research before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Pasithea Therapeutics Corp. Warrant

Exchange NASDAQ Headquaters Miami Beach, FL, United States
IPO Launch date 2021-09-15 CEO & Director Dr. Tiago Reis Marques M.D., Ph.D.
Sector Healthcare Website https://www.pasithea.com
Industry Biotechnology Full time employees 8
Headquaters Miami Beach, FL, United States
CEO & Director Dr. Tiago Reis Marques M.D., Ph.D.
Website https://www.pasithea.com
Website https://www.pasithea.com
Full time employees 8

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​